Matthew Hobart
Angel Investor @ The Rise Fund
San Francisco Bay Area, United States
Matthew Hobart is a private equity investor at The Rise Fund in San Francisco Bay Area focused on Medical and Health Care. Hobart is a Partner based in San Francisco. He leads the Healthcare and Financial Services sectors for TPG Growth. Matt is currently a board member of Petbarn and iMDsoft. Previous board service includes The Vincraft Group, Schiff Nutrition International, Wil Research and Agraquest.Prior to joining TPG Growth in 2004, Mr. Hobart was the VicePresident of Corporate Development for Critical Path, where he was part of a turnaround team that led Critical Path through a major financial and operational restructuring. Previously, Matt co-founded and served as a Managing Director of Vectis Group, a venture corporation that capitalized and built companies globally, in partnership with leading U.S. technology businesses. Prior to Vectis Group, Mr. Hobart made private equity investments in the US and Europe for the $2.2 billion Morgan Stanley Capital Partners III L.P. and helped raise and invest the $350 million Morgan Stanley Global Emerging Markets Fund.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 80%
Last updated:
For AI agents: llms.txt
Industries Matthew Hobart invests in
Stages Matthew Hobart invests in
Countries Matthew Hobart invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 3 (30%)
- Health Care 3 (30%)
- Biotechnology 3 (30%)
- Therapeutics 2 (20%)
- Biopharma 1 (10%)
Stage
- Private Equity 3 (30%)
- Series C 2 (20%)
- Venture - Series Unknown 2 (20%)
- Series D 1 (10%)
- Series E 1 (10%)
Country
- United States 6 (60%)
- India 1 (10%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| K2 Medical Research is a clinical research center that specializes in conducting clinical trials. | Private Equity / Jun 17, 2024 | ||
| RefleXion is developing the first biology-guided radiotherapy system, a significant change in strategy from single tumor therapy to the ability to one day treat multiple tumors in the same treatment session in cancers that have metastasized. Currently, the RefleXion X1 machine is cleared for the delivery of stereotactic body radiotherapy (SBRT),stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT). The company is also developing BgRT, which incorporates positron-emission tomography (PET) imaging data to enable tumors to continuously signal their location. The BgRT technology will synchronize these data with the linear accelerator to direct radiotherapy to tumors with subsecond latency. | $105M / Nov 15, 2023 | ||
| RefleXion is developing the first biology-guided radiotherapy system, a significant change in strategy from single tumor therapy to the ability to one day treat multiple tumors in the same treatment session in cancers that have metastasized. Currently, the RefleXion X1 machine is cleared for the delivery of stereotactic body radiotherapy (SBRT),stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT). The company is also developing BgRT, which incorporates positron-emission tomography (PET) imaging data to enable tumors to continuously signal their location. The BgRT technology will synchronize these data with the linear accelerator to direct radiotherapy to tumors with subsecond latency. | $80M / Series E / Mar 10, 2022 | ||
| Idaho College of Osteopathic Medicine is dedicated to training high-quality osteopathic physicians prepared to care for people. | Venture - Series Unknown / Feb 22, 2022 | ||
| Burrell College of Osteopathic Medicine is a private, investor-owned, free-standing, independently operated, and licensed college. | Venture - Series Unknown / Feb 22, 2022 | ||
| BGB Group is a marketing and advertising company providing marketing consulting and promotional advertising services. | Private Equity / Oct 14, 2021 | ||
| OneSource is a biopharmaceutical company that delivers affordable treatments to patients in both emerging and developed markets. It provides a one-stop-shop with comprehensive capabilities from cell line and process development through to scale up, cGMP manufacturing, and filling/finishing of proteins and peptides. Offer services at everystage of the development life cycle, from pre-clinical and clinical development to commercial Supply. At Stelis BioSource™, we assure customers of CDMO/CMO services our deep commitment to quality, service, and compliance. | $125M / Series C / Mar 19, 2021 | ||
| RefleXion is developing the first biology-guided radiotherapy system, a significant change in strategy from single tumor therapy to the ability to one day treat multiple tumors in the same treatment session in cancers that have metastasized. Currently, the RefleXion X1 machine is cleared for the delivery of stereotactic body radiotherapy (SBRT),stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT). The company is also developing BgRT, which incorporates positron-emission tomography (PET) imaging data to enable tumors to continuously signal their location. The BgRT technology will synchronize these data with the linear accelerator to direct radiotherapy to tumors with subsecond latency. | $100M / Series D / Apr 17, 2020 | ||
| RefleXion is developing the first biology-guided radiotherapy system, a significant change in strategy from single tumor therapy to the ability to one day treat multiple tumors in the same treatment session in cancers that have metastasized. Currently, the RefleXion X1 machine is cleared for the delivery of stereotactic body radiotherapy (SBRT),stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT). The company is also developing BgRT, which incorporates positron-emission tomography (PET) imaging data to enable tumors to continuously signal their location. The BgRT technology will synchronize these data with the linear accelerator to direct radiotherapy to tumors with subsecond latency. | $100M / Series C / Apr 04, 2018 | ||
| Precision Medicine Group is a specialized services company supporting next generation approaches to drug development and commercialization. Precision provides an integrated infrastructure that supports pharmaceutical and life science companies as they develop new products in the age of precision medicine. | $275M / Private Equity / Dec 19, 2017 |
Co-Investors
About The Rise Fund
The Rise Fund is committed to achieving social and environmental impact alongside financial returns. We seek to partner with creative entrepreneurs and build successful businesses that drive meaningful, measurable positive change.The Rise Fund will focus on investments in seven sectors in which independent research has shown that impact is bothachievable and measurable in quantitative terms: education, energy, food and agriculture, financial services, healthcare, information, and communication technology, and industrials and infrastructure.
The Rise Fund Contacts
| Name | Phone | Socials | |
|---|---|---|---|
John Rogers
Partner, Sector Lead
|
|||
Stephen Ellis
Senior Partner of Business Building
|
|||
Jim Coulter
Executive Chairman
|
|||
Michael R. Stone
CIO
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Matthew Hobart invest in?
Matthew Hobart invests primarily in Medical, Health Care and Biotechnology startups, most often at Private Equity and Series C stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Matthew Hobart?
Public channels for Matthew Hobart include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Matthew Hobart last invest?
The most recent investment recorded for Matthew Hobart closed in Jun 2024. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
